What is Jeff Brown’s Trending: Reduces Covid Hospitalizations 51%Can anyone provide some insight to what this drug may be and who produces it?
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Kaleido (KLDO) KB109 reduces covid hospitalization 51% but Pfizer’s paxlovid is better with 89%. KB109 better than Merck’s molnupiravir 30 %.
I’m waiting for RedHill Biopharma (RDHL) Phase 2/3 clininical trial result of it’s RHB-109 covid antiviral pill.
https://finance.yahoo.com/news/redhill-biopharma-ltd-announces-redhill-120200532.html
Kaleido Biosciences (KLDO) non-IND study of it’s KB109 a synthetic glycan “food” rather than a drug” reduced healthcare utilization by 51%.
https://www.benzinga.com/general/biotech/21/03/20316966/kaleido-biosciences-stock-is-trading-higher-on-positive-kb109-data-in-covid-19-study?utm_campaign=partner_feed&utm_source=yahooFinance&utm_medium=partner_feed&utm_content=site
Pfizer’s oral antiviral pill paxlovid reduced the risk of hospitalization or death by 89%. Merck molnupiravir was only 30% effective.
https://finance.yahoo.com/news/pharma-stock-roundup-fda-approves-141302497.html
RedHill Biopharma (RDHL) Announced today positive phase 2/3 clinical result of it’s antiviral drug Opaganib. Opaganib is indicated for severely ill hospitalized patients.
Results achieved in a severely ill hospitalized patient population with a median of 11-days from onset of symptoms – a patient population much further advanced than mild-moderate outpatients with less than 5 days from symptom onset, for which oral anti-viral medications (like Pfizer and Merk antiviral pills) have recently been approved